According to Philippine media reports, the Philippine Department of Agriculture is pushing for the Vietnamese AVAC ASF LIVE African swine fever live vaccine to enter the commercial sales phase. It is expected that the Bureau of Animal Industry will issue a commercial release certificate as early as the third quarter of 2026. If approved, the vaccine will be available for sale through veterinary bioproduct stores and veterinary shops registered with the Bureau of Animal Industry to support the recovery of the local swine industry.
Since the outbreak of African swine fever in 2019, the Philippine swine industry has remained under sustained pressure. The AVAC vaccine has previously entered the government-controlled vaccination and monitoring phase in the Philippines. Philippine officials have disclosed that the relevant vaccination program recorded approximately 90% vaccine efficacy and covered nearly 500,000 pigs. The Philippine Animal Industry Bureau stated that promoting the commercialization of the vaccine will help consolidate the momentum of the livestock industry’s recovery.
In terms of regional progress, Vietnam approved the commercial use of two domestically developed African swine fever vaccines—NAVET-ASFVAC and AVAC ASF LIVE—in 2023, becoming the first country in the world to commercialize ASF vaccines. Indonesia subsequently approved the use of AVAC ASF LIVE in 2025 and imported the vaccine. If the Philippines successfully completes the commercial release certification process, it will become the next Southeast Asian country—following Vietnam and Indonesia—to incorporate an African swine fever vaccine into its commercial supply system.
However, the commercialization of the vaccine does not mean that the pressure to prevent and control ASF has disappeared. The World Organization for Animal Health emphasizes that African swine fever vaccines should be used in accordance with strict quality standards, field evaluations, and post-vaccination monitoring, and should be combined with measures such as biosecurity, disease surveillance, and controls on animal movement. For the Philippines, the key challenges moving forward will be vaccination management following the opening of commercial channels, cold chain supervision, tracking of adverse reactions, and monitoring of viral mutations.
Disclaimer: Some of the information in this article is sourced from the internet. The sources have been clearly indicated, and copyright belongs to the original authors.
Since the outbreak of African swine fever in 2019, the Philippine swine industry has remained under sustained pressure. The AVAC vaccine has previously entered the government-controlled vaccination and monitoring phase in the Philippines. Philippine officials have disclosed that the relevant vaccination program recorded approximately 90% vaccine efficacy and covered nearly 500,000 pigs. The Philippine Animal Industry Bureau stated that promoting the commercialization of the vaccine will help consolidate the momentum of the livestock industry’s recovery.
In terms of regional progress, Vietnam approved the commercial use of two domestically developed African swine fever vaccines—NAVET-ASFVAC and AVAC ASF LIVE—in 2023, becoming the first country in the world to commercialize ASF vaccines. Indonesia subsequently approved the use of AVAC ASF LIVE in 2025 and imported the vaccine. If the Philippines successfully completes the commercial release certification process, it will become the next Southeast Asian country—following Vietnam and Indonesia—to incorporate an African swine fever vaccine into its commercial supply system.
However, the commercialization of the vaccine does not mean that the pressure to prevent and control ASF has disappeared. The World Organization for Animal Health emphasizes that African swine fever vaccines should be used in accordance with strict quality standards, field evaluations, and post-vaccination monitoring, and should be combined with measures such as biosecurity, disease surveillance, and controls on animal movement. For the Philippines, the key challenges moving forward will be vaccination management following the opening of commercial channels, cold chain supervision, tracking of adverse reactions, and monitoring of viral mutations.
Disclaimer: Some of the information in this article is sourced from the internet. The sources have been clearly indicated, and copyright belongs to the original authors.